Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 14UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Capecitabine 15Paclitaxel 13S 1 (combination) 9apatinib 8Oxaliplatin 8Carboplatin 8Cisplatin 7pyrotinib 6Epirubicin 6Docetaxel 6sintilimab 5camrelizumab 5anlotinib 5Radiotherapy 5Drug Therapy 5130-nm albumin-bound paclitaxel 5nimotuzumab 4nedaplatin 4Vinorelbine 4Temozolomide 4Irinotecan 4Fulvestrant 4Etoposide 4Bevacizumab 4toripalimab 3titanium silicide 3exemestane 3Trastuzumab 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × UNKNOWN × lobaplatin × Clear all
NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡